ELOXX PHARMACEUTICALS INC (ELOX) Fundamental Analysis & Valuation

NASDAQ:ELOX • US29014R2022

Current stock price

3.82 USD
-0.23 (-5.68%)
At close:
2.8 USD
-1.02 (-26.7%)
After Hours:

This ELOX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ELOX Profitability Analysis

1.1 Basic Checks

  • In the past year ELOX has reported negative net income.
  • In the past year ELOX has reported a negative cash flow from operations.
ELOX Yearly Net Income VS EBIT VS OCF VS FCFELOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -407.11%, ELOX is not doing good in the industry: 95.69% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -407.11%
ROE N/A
ROIC N/A
ROA(3y)-149.72%
ROA(5y)-125.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELOX Yearly ROA, ROE, ROICELOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 -500 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ELOX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELOX Yearly Profit, Operating, Gross MarginsELOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ELOX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ELOX remains at a similar level compared to 1 year ago.
  • Compared to 1 year ago, ELOX has a worse debt to assets ratio.
ELOX Yearly Shares OutstandingELOX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ELOX Yearly Total Debt VS Total AssetsELOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • ELOX has an Altman-Z score of -82.04. This is a bad value and indicates that ELOX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -82.04, ELOX is doing worse than 96.65% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -82.04
ROIC/WACCN/A
WACCN/A
ELOX Yearly LT Debt VS Equity VS FCFELOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

  • ELOX has a Current Ratio of 0.25. This is a bad value and indicates that ELOX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.25, ELOX is doing worse than 94.74% of the companies in the same industry.
  • ELOX has a Quick Ratio of 0.25. This is a bad value and indicates that ELOX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of ELOX (0.25) is worse than 94.26% of its industry peers.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
ELOX Yearly Current Assets VS Current LiabilitesELOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ELOX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 43.20% over the past year.
EPS 1Y (TTM)43.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ELOX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.36% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.16%
EPS Next 2Y24.25%
EPS Next 3Y16.7%
EPS Next 5Y23.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELOX Yearly Revenue VS EstimatesELOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2027 50M 100M 150M
ELOX Yearly EPS VS EstimatesELOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -20 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. ELOX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ELOX. In the last year negative earnings were reported.
  • Also next year ELOX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELOX Price Earnings VS Forward Price EarningsELOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELOX Per share dataELOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ELOX's earnings are expected to grow with 16.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.25%
EPS Next 3Y16.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ELOX Dividend Analysis

5.1 Amount

  • No dividends for ELOX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ELOX Fundamentals: All Metrics, Ratios and Statistics

ELOXX PHARMACEUTICALS INC

NASDAQ:ELOX (10/13/2023, 8:00:02 PM)

After market: 2.8 -1.02 (-26.7%)

3.82

-0.23 (-5.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11
Earnings (Next)11-08
Inst Owners0%
Inst Owner Change0%
Ins Owners156.5%
Ins Owner Change0%
Market Cap10.70M
Revenue(TTM)N/A
Net Income(TTM)-24.40M
Analysts85.71
Price Target61.2 (1502.09%)
Short Float %0.08%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.75%
Min EPS beat(2)-24.78%
Max EPS beat(2)-10.73%
EPS beat(4)2
Avg EPS beat(4)-3.03%
Min EPS beat(4)-24.78%
Max EPS beat(4)19.79%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.09%
PT rev (3m)20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.23%
EPS NY rev (1m)-10.63%
EPS NY rev (3m)4.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.36
EYN/A
EPS(NY)-7.54
Fwd EYN/A
FCF(TTM)-7.69
FCFYN/A
OCF(TTM)-7.67
OCFYN/A
SpS0
BVpS-6.64
TBVpS-6.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -407.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-149.72%
ROA(5y)-125.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z -82.04
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.17%
EPS Next Y51.16%
EPS Next 2Y24.25%
EPS Next 3Y16.7%
EPS Next 5Y23.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y47.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.61%
OCF growth 3YN/A
OCF growth 5YN/A

ELOXX PHARMACEUTICALS INC / ELOX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ELOXX PHARMACEUTICALS INC (ELOX) stock?

ChartMill assigns a fundamental rating of 0 / 10 to ELOX.


Can you provide the valuation status for ELOXX PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ELOXX PHARMACEUTICALS INC (ELOX). This can be considered as Overvalued.


Can you provide the profitability details for ELOXX PHARMACEUTICALS INC?

ELOXX PHARMACEUTICALS INC (ELOX) has a profitability rating of 0 / 10.


What is the financial health of ELOXX PHARMACEUTICALS INC (ELOX) stock?

The financial health rating of ELOXX PHARMACEUTICALS INC (ELOX) is 0 / 10.